{
  "source": "PA-Notification-Gomekli.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1476-1\nProgram Prior Authorization/Notification\nMedication Gomekli™ (mirdametinib)\nP&T Approval Date 4/2025\nEffective Date 7/1/2025\n1. Background:\nGomekli is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age\nand older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN)\nnot amenable to complete resection.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of 19\nyears, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Gomekli will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Neurofibromatosis Type 1\n1. Initial Authorization\na. Gomekli will be based approved based on both of the following:\n(1) Diagnosis of neurofibromatosis type 1\n-AND-\n(2) Patient has plexiform neurofibromas (PN) that are both of the following:\n(a) Symptomatic\n(b) Not amenable to complete resection\n© 2025 UnitedHealthcare Services Inc.\n1\nAuthorization will be issued for 12 months.\n1. Reauthorization\na. Gomekli will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Gomekli therapy.\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of\nEvidence and Consensus of 1, 2A, or 2B.\nAuthorization wi",
    "ed for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of\nEvidence and Consensus of 1, 2A, or 2B.\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n• Gomekli™ [package insert]. Stamford, CT: SpringWorks Therapeutics, Inc; February, 2025.\nProgram Prior Authorization/Notification - Gomekli™ (mirdametinib)\nChange Control\n4/2025 New program.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}